OBJECTIVE: To evaluate the safety and pharmacokinetic interaction between GW433908, ritonavir (RTV), and efavirenz (EFV). METHODS: In period 1, subjects received either a once daily (QD) regimen of GW433908 1395mg + RTV 200 mg (Study 1) or a twice daily (bid) regimen of GW433908 700 mg + RTV 100 mg (Study 2) for 14 days. In period 2, subjects received EFV 600 mg QD with either the same GW433908 + RTV regimen as in period 1 (arm 1) or with a GW433908 + RTV regimen that included an additional 100 mg of RTV (arm 2) for 14 days. Amprenavir (APV) pharmacokinetic sampling and safety assessments were performed on the last day of each period. RESULTS:Plasma APV exposure was not significantly altered when EFV was coadministered with GW433908 700 mg twice daily (BID) + RTV 100 mg BID. Plasma APV exposure was decreased when EFV was coadministered with GW433908 1395mg QD + RTV 200 mg QD. However, administration of EFV with GW433908 1395mg QD + RTV 300 mg QD (i.e., adding an extra 100 mg of RTV) was able to negate this interaction. Adverse events were consistent with prior data for each of the separate agents. CONCLUSION: When EFV is coadministered with the GW433908 700 mg + RTV 100 mg BID regimen, no dosage adjustment is recommended. However, when EFV is coadministered with the GW433908 1400mg + RTV 200 mg QD regimen, an increase to RTV 300 mg QD is needed to maintain plasma APV exposure.
RCT Entities:
OBJECTIVE: To evaluate the safety and pharmacokinetic interaction between GW433908, ritonavir (RTV), and efavirenz (EFV). METHODS: In period 1, subjects received either a once daily (QD) regimen of GW433908 1395 mg + RTV 200 mg (Study 1) or a twice daily (bid) regimen of GW433908 700 mg + RTV 100 mg (Study 2) for 14 days. In period 2, subjects received EFV 600 mg QD with either the same GW433908 + RTV regimen as in period 1 (arm 1) or with a GW433908 + RTV regimen that included an additional 100 mg of RTV (arm 2) for 14 days. Amprenavir (APV) pharmacokinetic sampling and safety assessments were performed on the last day of each period. RESULTS: Plasma APV exposure was not significantly altered when EFV was coadministered with GW433908 700 mg twice daily (BID) + RTV 100 mg BID. Plasma APV exposure was decreased when EFV was coadministered with GW433908 1395 mg QD + RTV 200 mg QD. However, administration of EFV with GW433908 1395 mg QD + RTV 300 mg QD (i.e., adding an extra 100 mg of RTV) was able to negate this interaction. Adverse events were consistent with prior data for each of the separate agents. CONCLUSION: When EFV is coadministered with the GW433908 700 mg + RTV 100 mg BID regimen, no dosage adjustment is recommended. However, when EFV is coadministered with the GW433908 1400 mg + RTV 200 mg QD regimen, an increase to RTV 300 mg QD is needed to maintain plasma APV exposure.
Authors: Edwin DeJesus; Peter J Piliero; Kim Summers; Mary Beth Wire; Daniel S Stein; Amanda Masterman; Yu Lou; Sherene S Min; Mark J Shelton Journal: Antimicrob Agents Chemother Date: 2006-09 Impact factor: 5.191
Authors: Gene D Morse; Susan Rosenkranz; Michael F Para; Yoninah Segal; Robin Difrancesco; Elizabeth Adams; Barbara Brizz; Kevin E Yarasheski; Richard C Reichman Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: Mary B Wire; Katherine L Baker; Lori S Jones; Mark J Shelton; Yu Lou; Greg J Thomas; M Michelle Berrey Journal: Antimicrob Agents Chemother Date: 2006-04 Impact factor: 5.191
Authors: Y Sunila Reddy; Susan L Ford; Maggie T Anderson; Sharon C Murray; Judith Ng-Cashin; Mark A Johnson Journal: Antimicrob Agents Chemother Date: 2007-01-29 Impact factor: 5.191
Authors: Peter J Ruane; Andrew D Luber; Mary Beth Wire; Yu Lou; Mark J Shelton; C Tracey Lancaster; Keith A Pappa Journal: Antimicrob Agents Chemother Date: 2006-11-06 Impact factor: 5.191
Authors: Qing Ma; Alan Forrest; Susan L Rosenkranz; Michael F Para; Kevin E Yarasheski; Richard C Reichman; Gene D Morse Journal: Biopharm Drug Dispos Date: 2008-03 Impact factor: 1.627